Biogen | BIIB - Sales Revenues



Biogen reported $2.6B in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
AbbVie USD 15.42B 2.08B Jun/2025
Acadia Pharmaceuticals USD 264.6M 20.28M Jun/2025
ALKERMES USD 390.7M 84.2M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
Bayer EUR 10.74B 3B Jun/2025
Biogen USD 2.6B 170M Jun/2025
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
Incyte USD 1.06B 10M Jun/2025
Merck USD 15.81B 280M Jun/2025
Moderna USD 142M 34M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
PTC Therapeutics USD 178.9M 11.1M Jun/2025
Regeneron Pharmaceuticals USD 3.68B 650M Jun/2025
Sanofi EUR 9.99B 90M Jun/2025
Sanofi EUR 10.74B 529.51M Jun/2025
Sarepta Therapeutics USD 611.09M 163.81M Jun/2025
Teva Pharmaceutical Industries USD 14.06B 0 Jun/2025
Ultragenyx Pharmaceutical USD 166.5M 27.21M Jun/2025
United Therapeutics USD 798.6M 4.2M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025